SCHEDULE: Avoro Capital Discloses 9.95% Stake in Tourmaline Bio
Beneficial Ownership Statement
Avoro Capital Advisors LLC and Behzad Aghazadeh have reported a 9.95% beneficial ownership stake in Tourmaline Bio, Inc. for investment purposes.
Summary
- Avoro Capital Advisors LLC and Behzad Aghazadeh collectively beneficially own 2,555,555 shares of Tourmaline Bio, Inc. Common Stock.
- This ownership represents 9.95% of Tourmaline Bio, Inc.'s total outstanding Common Stock.
- The shares were acquired and are held solely for investment purposes, without the intent to change or influence the control of the issuer.
- The percentage of ownership is calculated based on 25,688,479 shares of Common Stock outstanding as of April 25, 2025, as reported in the company's Quarterly Report on Form 10-Q.
Sentiment
Score: 6
Explanation: Neutral to slightly positive. A significant stake by an institutional investor is generally seen as a positive signal, but the filing itself is purely factual and does not contain operational or financial performance data.
Positives
- A significant institutional investor, Avoro Capital Advisors, has taken a substantial stake, indicating potential confidence in Tourmaline Bio's long-term prospects.
- The acquisition is stated to be solely for investment purposes, suggesting a passive, long-term view rather than an activist intent.
Future Outlook
This filing does not contain forward-looking statements or guidance regarding the company's future performance or operations, as it is solely a beneficial ownership disclosure.
Industry Context
This filing indicates a significant investment by a specialized life sciences fund in Tourmaline Bio, suggesting a potential belief in the company's long-term value within the biotechnology or pharmaceutical sector. Such investments are common as funds seek to gain exposure to promising companies in the industry.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake may instill confidence and potentially influence market perception.
Key Dates
| Date | Description |
|---|---|
| 2025-04-25 | Date as of which 25,688,479 shares of Common Stock were reported outstanding in the Company's Form 10-Q. |
| 2025-05-02 | Date Tourmaline Bio, Inc. filed its Quarterly Report on Form 10-Q for the period ended March 31, 2025. |
| 2025-06-30 | Date of event which required the filing of this Schedule 13G statement. |
| 2025-08-14 | Date the Schedule 13G Amendment No. 1 was signed and filed. |
Keywords
Tourmaline Bio, Avoro Capital Advisors, Behzad Aghazadeh, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Investment, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.